• 1
    Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology 2003; 110: 9625.
  • 2
    Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107: 14439.
  • 3
    Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005; 18: 14350.
  • 4
    Saraiva VS, Edelstein C, Burnier MN,Jr. New prognostic factors in uveal melanomas: potential molecular targets for therapy. Can J Ophthalmol 2004; 39: 4227.
  • 5
    Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 72059.
  • 6
    Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004; 40: 262332.
  • 7
    Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 30413.
  • 8
    Srinivas PR, Srivastava S, Hanash S, Wright GL,Jr. Proteomics in early detection of cancer. Clin Chem 2001; 47: 190111.
  • 9
    Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002; 19: 31926.
  • 10
    Pardo M, Pineiro A, de la Fuente M, Garcia A, Prabhakar S, Zitzmann N, Dwek RA, Sanchez-Salorio M, Dominguez F, Capeans C. Abnormal cell cycle regulation in primary human uveal melanoma cultures. J Cell Biochem 2004; 93: 70820.
  • 11
    Pardo M, Garcia A, Thomas B, Pineiro A, Akoulitchev A, Dwek RA, Zitzmann N. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics 2005; 5: 498093.
  • 12
    Sanchez JC, Rouge V, Pisteur M, Ravier F, Tonella L, Moosmayer M, Wilkins MR, Hochstrasser DF. Improved and simplified in-gel sample application using reswelling of dry immobilized pH gradients. Electrophoresis 1997; 18: 3247.
  • 13
    Hassner A, Birnbaum D, Loew LM. Charge-shift probes of membrane potential synthesis. J Org Chem 1984; 49: 254651.
  • 14
    O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, Hebestreit HF. Towards complete analysis of the platelet proteome. Proteomics 2002; 2: 288305.
  • 15
    Shevchenko A, Jensen ON, Podtelejnikov AV, Sagliocco F, Wilm M, Vorm O, Mortensen P, Shevchenko A, Boucherie H, Mann M. Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc Natl Acad Sci USA 1996; 93: 144405.
  • 16
    Diebold Y, Blanco G, Saornil MA, Fernandez N, Lazaro MC. Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived). Curr Eye Res 1997; 16: 48795.
  • 17
    Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001; 7: 332835.
  • 18
    Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, Iizuka N, Ueyama Y, Nakamura K. Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005; 5: 102432.
  • 19
    Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, Folberg R, Hendrix MJ. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 2002; 19: 23346.
  • 20
    Seike M, Kondo T, Fujii K, Yamada T, Gemma A, Kudoh S, Hirohashi S. Proteomic signature of human cancer cells. Proteomics 2004; 4: 277688.
  • 21
    Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 22735.
  • 22
    Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 23644.
  • 23
    Marshall JC, Caissie AL, Burnier MN,Jr. How in vitro techniques have increased our understanding of uveal melanoma cellular biology. Can J Ophthalmol 2004; 39: 42832.
  • 24
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 2347.
  • 25
    Wang K, Shindoh H, Inoue T, Horii I. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J Toxicol Sci 2002; 27: 22937.
  • 26
    De Saint Jean M, Baudouin C, Di Nolfo M, Roman S, Lozato P, Warnet JM, Brignole F. Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang conjunctival cell line. Exp Eye Res 2004; 78: 25774.
  • 27
    Garcia-Pedrero JM, Fernandez MP, Morgan RO, Zapatero AH, Gonzalez MV, Nieto CS, Rodrigo JP. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004; 164: 739.
  • 28
    Karube A, Shidara Y, Hayasaka K, Maki M, Tanaka T. Suppression of calphobindin I (CPB I) production in carcinoma of uterine cervix and endometrium. Gynecol Oncol 1995; 58: 295300.
  • 29
    Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, Hart IR. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res 1996; 56: 38558.
  • 30
    Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 2000; 18: 51925.
  • 31
    Fella K, Gluckmann M, Hellmann J, Karas M, Kramer PJ, Kroger M. Use of two-dimensional gel electrophoresis in predictive toxicology: identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics 2005; 5: 191427.
  • 32
    Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers. Lab Invest 1998; 78: 15363.
  • 33
    Giancotti V, Buratti E, Perissin L, Zorzet S, Balmain A, Portella G, Fusco A, Goodwin GH. Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp Cell Res 1989; 184: 53845.
  • 34
    Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol 2004; 88: 8699.
  • 35
    Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001; 21: 57594.
  • 36
    Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 98915.
  • 37
    Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999; 189: 411.
  • 38
    Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996; 218: 21016.
  • 39
    McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002; 1: 45965.
  • 40
    Iwamoto S, Burrows RC, Grossniklaus HE, Orcutt J, Kalina RE, Boehm M, Bothwell MA, Schmidt R. Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. Arch Ophthalmol 2002; 120: 16259.
  • 41
    Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology 2000; 58: 838.
  • 42
    Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001; 279: 1731.
  • 43
    van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001; 61: 63404.
  • 44
    Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 1990; 110: 122737.
  • 45
    Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002; 62: 510614.
  • 46
    Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 50913.
  • 47
    Okada M, Matsumoto K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. Biol Pharm Bull 2002; 25: 8536.
  • 48
    Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM, Ariga H. DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res 2003; 1: 24761.
  • 49
    Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004; 101: 91038.
  • 50
    Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, Heutink P. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 2003; 24: 159, 160.
  • 51
    MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIα. Cancer Res 2003; 63: 692834.
  • 52
    Hod Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem 2004; 92: 122133.
  • 53
    Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 26373.
  • 54
    Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 257884.